Global Drug-Induced Cardiotoxicity Market Analysis By Type (Chemotherapy-Induced Cardiotoxicity, Antipsychotic Drug-Induced Cardiotoxicity), By Detection (Biomarkers, Imaging Techniques), By Drug Class (Tyrosine Kinase Inhibitors (TKIs), Antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Apr 2024
- Report ID: 73803
- Number of Pages: 295
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
Drug-Induced Cardiotoxicity Market: Drug-induced cardiotoxicity is a major cause of compound failure in preclinical and clinical trials. It is one of the most significant side-effects associated with the development of new pharmaceuticals, and it is also one of the most common toxic consequences caused by several drugs. Cardiotoxicity is not limited to anti-cancer drugs; nearly every therapeutic medication type can cause unforeseen cardiotoxicity.
Cardiotoxicity caused by persistently administered medications, such as neurologic/psychiatric treatments and anticancer chemotherapeutic agents, are major issues, since toxicity may not be apparent until the drug or its metabolites have accumulated for a long time.
Drug-induced cardiotoxicity risk, including QT interval prolongation, is now a standard aspect of the preclinical evaluation of new entities of chemicals, as established by the International Conference of Harmonization Expert Working Group for all medications in development.
Surprisingly, nearly 10% of drugs have been withdrawn from the clinical market globally due to cardiovascular safety concerns in the last four decades, including tegaserod, rofecoxib, and sibutramine, despite significant efforts to detect cardiotoxicity in the preclinical phase of medicinal product development, cardiotoxicity continues to be a major source of safety concerns, owing to a lack of sufficient knowledge about cardiotoxicity mechanisms.
Key Market Segments
Type
- Chemotherapy-Induced Cardiotoxicity
- Antipsychotic Drug-Induced Cardiotoxicity
Detection
- Biomarkers
- Imaging Techniques
Drug Class
- Tyrosine Kinase Inhibitors (TKIs)
- Antibiotics
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Drivers
The use of targeted anticancer medicines has had a positive impact on drug-induced cardiotoxicity industry advancements. There has been an increase in the number of patients recuperating from cancer in many countries throughout the world, which has resulted in an increase in oncology research, which will lead to a reduction in cardiovascular illnesses. As a result, most doctors around the world benefit from increased cancer research activities as the market for drug-induced cardiotoxicity advances.
Drug-induced cardiotoxicity therapy products are in high demand due to increasing life expectancy and healthcare spending in both developed and developing countries. These are certain factors that will help augment this target market’s revenue growth trajectory in the years to come.
Restraints
The further expansion of the global drug-induced cardiotoxicity market is projected to be hampered by stringent enforced regulations for drug approval. Additionally, weaker economic conditions in regions such as the Middle East and Africa have a lower rate of diagnosis and treatment uptake, thereby also posing a challenge to the global drug-induced cardiotoxicity market’s financial growth. Moreover, a lack of sufficient information and expertise about drug-induced cardiotoxicity could restrict the revenue growth of this market.
Opportunities
Booming geriatric populations, which are commonly affected with various types of cancer and cardiovascular disorders. This factor is expected to increase opportunities for industry players improve their prospects of amplifying their existing sales figures. This in turn, is expected to foster the development of novel drugs that may eventually lead to greater market growth opportunities.
Key Regions
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Market Key Players
- Novartis AG
- Pfizer Inc
- Siemens Healthineers
- GE Healthcare
- Amgen Inc
- Bristol Myers Squibb
- Mayo Clinic
- Cleveland Clinic
Report Scope
Report Features Description Base Year for Estimation 2023 Historic Period 2018-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Type (Chemotherapy-Induced Cardiotoxicity, Antipsychotic Drug-Induced Cardiotoxicity), By Detection (Biomarkers, Imaging Techniques), By Drug Class (Tyrosine Kinase Inhibitors (TKIs), Antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)) Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Novartis AG, Pfizer Inc, Siemens Healthineers, GE Healthcare, Amgen Inc, Bristol Myers Squibb, Mayo Clinic, Cleveland Clinic Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Drug-Induced Cardiotoxicity MarketPublished date: Apr 2024add_shopping_cartBuy Now get_appDownload Sample - Novartis AG Company Profile
- Pfizer Inc Company Profile
- Siemens Healthineers
- GE Healthcare
- Amgen Inc
- Bristol Myers Squibb Company Profile
- Mayo Clinic
- Cleveland Clinic
- settingsSettings
Our Clients
Single User $4,599 $3,499 USD / per unit save 24% | Multi User $5,999 $4,299 USD / per unit save 28% | Corporate User $7,299 $4,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,499) | Buy Now ($ 4,299) | Buy Now ($ 4,999) |